<DOC>
	<DOC>NCT01968109</DOC>
	<brief_summary>To assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated dose of BMS-986016 alone and in combination with Nivolumab in subjects with select advanced (metastatic and/or unresectable) solid tumors and to provide preliminary information on the clinical benefits of the combination.</brief_summary>
	<brief_title>Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms by Site</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. For Dose escalation: subjects with cervical, ovarian, bladder and CRC, head and neck, gastric and hepatocellular cancer naive to immunooncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with antiPD1/antiPDL1 and melanoma subjects progressed whileon or after treatment with antiPD1 or antiPDL1 with or without antiCTLA4. For Dose Expansion: all of the above in escalation except for cervical, ovarian bladder and CRC Progressed, or been intolerant to, at least one standard treatment regimen, except for subjects in 1st line cohorts. ECOG performance status of 0 or 1 At least 1 lesion with measurable disease at baseline Availability of an existing tumor biopsy sample (and consent to allow pretreatment tumor biopsy) Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease Autoimmune disease Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent Uncontrolled CNS metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>